Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

Core Viewpoint - Glucotrack, Inc. will implement a 1-for-60 reverse stock split effective June 16, 2025, to comply with Nasdaq's minimum bid price requirement and attract institutional investors [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the total outstanding shares from 32,541,327 to approximately 542,356 shares [8]. - Each stockholder's ownership percentage will remain unchanged, except for fractional shares, which will be rounded up to the next whole share [8]. - The new CUSIP number for the Common Stock post-split will be 45824Q804 [2]. Group 2: Compliance and Strategic Intent - The reverse stock split aims to bring Glucotrack into compliance with the $1.00 minimum bid price requirement for Nasdaq listing [3]. - The company may face delisting if it becomes deficient with any Nasdaq Listing Rule before September 29, 2025 [3]. Group 3: Company Overview - Glucotrack focuses on developing novel technologies for diabetes management, including a long-term implantable continuous blood glucose monitoring system [7][9].